Compare MPB & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPB | PHAR |
|---|---|---|
| Founded | 1868 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 856.0M | 1.2B |
| IPO Year | 1996 | 2020 |
| Metric | MPB | PHAR |
|---|---|---|
| Price | $32.45 | $12.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $37.00 | ★ $38.33 |
| AVG Volume (30 Days) | ★ 106.5K | 10.4K |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.95 | $10.04 |
| Revenue Next Year | $9.45 | $2.51 |
| P/E Ratio | ★ $90.63 | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.83 | $9.54 |
| 52 Week High | $35.22 | $21.34 |
| Indicator | MPB | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 48.99 | 31.19 |
| Support Level | $30.66 | $11.43 |
| Resistance Level | $34.88 | $17.41 |
| Average True Range (ATR) | 0.80 | 0.53 |
| MACD | 0.01 | -0.09 |
| Stochastic Oscillator | 50.90 | 15.28 |
Mid Penn Bancorp Inc is a financial holding company, providing various banking and financial products and services through its subsidiaries. These products and services mainly include consumer banking products, including secure checking and savings accounts, mobile banking, agricultural loans, construction financing, mortgages, home equity loans and lines of credit, credit cards, and more. Additionally, the Group offers trust services, insurance products, wealth management, and private banking services. The Group caters to individuals, partnerships, non-profit organizations, and corporations through its retail banking offices located throughout Pennsylvania, with a minor portion in New Jersey.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.